HHidalgo
TL2 Member · Bremen, DE
UK-based. Mostly the access and pricing categories.
Joined 26 December 2024 · last posted 17d · groups: regional-uk
71Posts here
0Topics
1Solutions
417Likes received
290Likes given
19Badges
129Days visited
1.4kPosts read
Stated areas
Recent activity
Full stream-
[2026 update] Travelling with an injectable: documentation and practicalities Replied, post #72 · Access › International · 11 Jul 2026 · 3 likes Coming back to post #70, because the follow-up matters more than the original answer. Customs and import outcomes: different routes have different seizure rates. Some…
-
Reading a rodent study on a secretagogue without over-extrapolating — the long version Replied, post #34 · Compounds › Secretagogues & GH axis · 11 Jul 2026 · 18 likes Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own…
-
What to include when your question involves a laboratory result Replied, post #11 · Start Here › How to Ask · 10 Jul 2026 · 5 likes Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing. The correction was fair and I had…
-
What is genuinely unknown about long-term amylin agonism Replied, post #7 · Compounds › Cagrilintide & amylin analogues · 6 Jul 2026 · 1 like This follows post #4 rather than contradicting it. Historical amylin analogues: pramlintide was the only long-acting amylin analogue licensed for some time and its poor…
-
Personal or family history of medullary thyroid carcinoma Replied, post #6 · Safety › Contraindications · 22 Jun 2026 · 12 likes Pregnancy: these compounds are not approved for pregnancy. The potential risks outweigh potential benefits. Planning windows and washout (several months) are the…
-
Review: a draft on reconstitution arithmetic, with objections — one year on Replied, post #28 · Documentation › Doc review · 15 Jun 2026 · 14 likes Picking up post #25: that is the part I would want checked first. Multilingual versions: if a maintained page should exist in another language, suggesting it here with…
-
[2026 update] A vial that will not fully dissolve: what to check and in what order Replied, post #94 · Practice › Reconstitution · 7 Jun 2026 · 0 likes Arithmetic step by step: a 5 mg vial with 2 mL of diluent gives (5 mg) / (2 mL) = 2.5 mg/mL. On a U-100 syringe at that concentration, 100 units = 1 mL = 2.5 mg, so…
-
Coming back to: Time to steady state after a dose increase Replied, post #69 · Pharmacology › Pharmacokinetics · 5 Jun 2026 · 5 likes On post #65 — agreed on the reasoning, with one qualification. Renal clearance: these compounds are cleared partly via the kidney. In severe renal impairment, clearance…
-
Comparing prices across jurisdictions without misleading yourself Replied, post #37 · Access › Pricing · 4 Jun 2026 · 11 likes Picking up post #34: that is the part I would want checked first. Cost per milligram is the only comparison that survives format differences, but even then it needs…
-
Journal club: orforglipron phase 2 and the non-peptide question Replied, post #80 · Evidence › Journal club · 2 Jun 2026 · 12 likes STEP 1 (N Engl J Med 2021): The pivotal obesity trial for semaglutide and the reference point for most subsequent comparison. Mean weight reduction was substantially…
-
Interim analyses and stopping rules Replied, post #25 · Evidence › Trials · 1 Jun 2026 · 0 likes Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can…
-
Molecular mass of semaglutide and why the figure differs between sources Replied, post #66 · Compounds › Semaglutide · 29 May 2026 · 5 likes The opalescent appearance in semaglutide solutions is occasionally noted and the mechanism is unclear. It does not appear to correlate with product failure in practice.…